masivet
ab science s.a. - masitinib mesilate - antineoplastiset aineet - koirat - kohdistamattomien koiran mastasolusyöpäaineiden (luokka 2 tai 3) hoito vahvistetulla mutatoidulla c-kit-tyrosiinikinaasireseptorilla.
masipro
ab science - masitinib mesilate - mastosytoosi - antineoplastiset aineet - hoito mastosytoosi.
alsitek
ab science - masitinib mesilate - amyotrofinen lateraaliskleroosi - antineoplastiset aineet - hoito amyotrofinen lateraaliskleroosi.
masiviera
ab science - masitinib - haimasyöpä - proteiinikinaasin estäjät - hoito ei resectable paikallisesti pitkälle edennyt tai metastaattinen haimasyöpä.
masican
masitinib - ruoansulatuskanavan stromal-kasvaimet - proteiinikinaasin estäjät - hoito, jota ei voitu leikata ja/tai metastasoituneen pahanlaatuisen gastrointestinaalinen stroomakasvain (gist).
dasatinib accord
accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinibin - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiset aineet - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
dasatinib stada 20 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - dasatinib - tabletti, kalvopäällysteinen - 20 mg - dasatinibi
dasatinib stada 50 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - dasatinib - tabletti, kalvopäällysteinen - 50 mg - dasatinibi
dasatinib stada 70 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - dasatinib - tabletti, kalvopäällysteinen - 70 mg - dasatinibi